AKT1 and malignant pleural mesothelioma: Another promising combination is the potential use of locally administered microRNA-206 (which has been shown to target the RTK-Ras-MAPK-P13K/Akt-CDK pathway) and CDK4/6i, such as Abemaciclib, following successful in vitro and in vivo studies in malignant pleural mesothelioma [48].